Tirzepatide

A cutting-edge, dual-action injectable medication 
Combining GLP-1 and GIP receptor agonists to improve metabolic health and aid in weight loss

Combining GLP-1 and GIP receptor agonists to improve metabolic health and aid in weight loss

How It Works:
  • Dual receptor activation: Stimulates GLP-1 and GIP receptors to  improve insulin secretion and decrease insulin resistance.
  • Appetite regulation: Slows digestion and reduces hunger by signaling  satiety to the brain.
  • Blood sugar management: Lowers post-meal glucose spikes and  stabilizes blood sugar levels.
Who is not eligible:
  • Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
  • Those with severe gastrointestinal conditions or pancreatitis.
  • Pregnant or breastfeeding individuals.
  • This is not an exhaustive list of side effects or eligibility criteria.
    More detailed information will be provided during your consultation.

Leave a Reply